Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Genzyme 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Genzyme 4Q

Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 4Q

4Q Revenues: $1.1 billion (-8%)

4Q Earnings: $23.2 million (earnings were $86.7 million in 4Q08)

FY Revenues: $4.5 billion (-2%)

FY Revenues: $422.3 million (flat)

Comments: Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption. Cerezyme sales were $105.4 million (-66%), and Fabrazyme sales were down 54% to $58.0 million. Cardiometabolic and Renal sales in the quarter were $259.2 million (+7%). Renagel and Renvela sales were $178.9 million (+6%). Hematologic Oncology revenue was $108.3 million in the quarter (+154%). R&D expenses were down 36% in the quarter to $228.5 million.


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters